| Literature DB >> 31480659 |
Minghui Wang1,2, Longhe Yang1, Liubin Feng3, Fan Hu1, Fang Zhang1, Jie Ren4, Yan Qiu5, Zhaokai Wang6.
Abstract
In an effort to discover new bioactive anti-tumor lead compounds, a specific tyrosine phosphatase CDC25B and an Erb family receptor EGFR were selected as drug screening targets. This work led to the investigation of the soft coral-derived fungus Talaromyces verruculosus and identification of two new oligophenalenone dimers, verruculosins A-B (1-2), along with three known analogues, bacillisporin F (3), duclauxin (4), and xenoclauxin (5). Compound 1 was the first structure of the oligophenalenone dimer possessing a unique octacyclic skeleton. The detailed structures and absolute configurations of the new compounds were elucidated on the basis of spectroscopic data, X-ray crystallography, optical rotation, Electronic Circular Dichroism (ECD) analysis, and nuclear magnetic resonance (NMR) calculations. Among which, compounds 1, 3, and 5 exhibited modest inhibitory activity against CDC25B with IC50 values of 0.38 ± 0.03, 0.40 ± 0.02, and 0.26 ± 0.06 µM, respectively.Entities:
Keywords: Talaromyces verruculosus; oligophenalenone dimers; secondary metabolites; soft coral-derived fungus
Mesh:
Substances:
Year: 2019 PMID: 31480659 PMCID: PMC6780165 DOI: 10.3390/md17090516
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
1H (600 MHz) and 13C (150 MHz) NMR data for compounds 1–2 in CDCl3.
| No. | 1 | 2 | ||
|---|---|---|---|---|
|
|
| |||
| 1 | 5.06, ddd (10.2, 6.0, 2.4) | 69.1, CH | 5.56, dd (3.6, 10.2) | 70.6, CH |
| 3 | 169.5, C | 167.9, C | ||
| 3a | 101.2, C | 100.0, C | ||
| 3b | 134.6, C | 134.1, C | ||
| 4 | 161.9, C | 161.7, C | ||
| 5 | 6.55, s | 117.9, CH | 6.55, s | 118.0, CH |
| 6 | 149.0, C | 149.5, C | ||
| 6a | 117.5, C | 118.4, C | ||
| 7 | 87.0, C | 86.4, C | ||
| 8 | 3.59, d (2.4) | 56.9, CH | 3.73, s | 57.8, CH |
| 9 | 147.5, C | 150.9, C | ||
| 9a | 101.3, C | 103.9, C | ||
| 10 | 2.59, s | 21.2, CH3 | 2.59, s | 21.4, CH3 |
| 11 | α 2.46, q (6.0) | 36.3, CH2 | α 2.70, m | 39.7, CH2 |
| 12 | 99.9, C | 173.0, C | ||
| 13 | 1.74, s | 28.3, CH3 | 3.65, s | 52.9, CH3 |
| 14 | 2.93, s | 51.1, CH3 | 2.91, s | 50.8, CH3 |
| 1′ | α 4.94, d (12.0) | 71.1, CH2 | α 5.00, d (12.0) | 71.2, CH2 |
| 3′ | 168.0, C | 167.7, C | ||
| 3′a | 104.3, C | 104.5, C | ||
| 3′b | 143.5, C | 143.5, C | ||
| 4′ | 164.4, C | 164.4, C | ||
| 5′ | 6.63, br.d | 120.8, CH | 6.62, s | 120.8, CH |
| 6′ | 151.8, C | 151.4, C | ||
| 6′a | 121.1, C | 121.1, C | ||
| 7′ | 190.9, C | 191.0, C | ||
| 8′ | 4.16, s | 67.9, CH | 4.15, s | 68.2, CH |
| 9′ | 5.17, s | 76.8, CH | 5.16, s | 76.7, CH |
| 9′a | 51.4, C | 52.0, C | ||
| 10′ | 2.06, s | 22.2, CH3 | 2.07, s | 22.1, CH3 |
| 4-OH | 10.82, s | 10.85, s | ||
| 4′-OH | 11.71, s | 11.63, s | ||
| 9-OH | ||||
| OAc | 169.6, C | 169.7, C | ||
| 2.20, s | 21.0, CH3 | 2.21, s | 21.0, CH3 | |
Figure 1Structures of compounds 1–5.
Figure 2Key COSY and HMBC correlations of compounds 1–2.
Figure 3X-ray structure of compound 1.
Figure 4Key NOESY correlations of compounds 1–2.
Figure 5Electronic Circular Dichroism (ECD) spectra of compounds 1–5.
MAE, CMAE, MaxErr, CMaxErr, the correlation coefficient, and DP4 probability for 2.
| 1H | 13C | 1H | 13C | |
|---|---|---|---|---|
| MAE | 0.2396 | 3.1123 | 0.2565 | 3.2633 |
| CMAE | 0.2225 | 1.9137 | 0.2559 | 2.1154 |
| MaxErr | 0.594 | 7.678 | 0.861 | 9.162 |
| CMaxErr | 1.100 | 5.337 | 1.132 | 4.394 |
|
| 0.9937 | 0.9989 | 0.992 | 0.9987 |
| DP4 | 99.90% | 98.10% | 0.10% | 1.90% |
| DP4 * | 100.00% | 0.00% | ||
The best agreements are highlighted in bold type; r2: correlation coefficient; MAE: mean average error; CMAE: corrected mean average error; MaxErr: maximum error; CmaxErr: corrected maximum error; * The data include carbon and proton data.
Figure 6X-ray structure of compound 3.
The biological activities of compounds 1–5.
| Comp. | Anti-EGFRIC | Anti-CDC25BIC |
|---|---|---|
|
| 0.92 ± 0.25 | 0.38 ± 0.03 |
|
| 1.22 ± 0.53 | NT a |
|
| 4.41 ± 2.32 | 0.40 ± 0.02 |
|
| 0.95 ± 0.64 | 0.75 ± 0.18 |
|
| 0.24 ± 0.17 | 0.26 ± 0.06 |
| Afatinib | 0.0005 ± 0.00002 | NT a |
| Na3VO4 | NT a | 0.52 ± 0.02 |
a No test.